Research Chemical Designation & Liability
Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.
AOD-9604
Metabolic & Weight Loss
Molecular Dossier
- Rank Index: 13
- Status: FDA Category 1
- What does this mean?
- Molecular Structure: C-Terminal HGH Fragment
About AOD-9604
AOD-9604 (Advanced Obesity Drug, residues 176–191 of human growth hormone) is a 16-amino-acid peptide fragment that activates the GH secretagogue receptor without the metabolic side effects of full GH therapy. Originally developed by Axis Biotech. Mechanism: selective lipolysis activation via receptor signaling without insulin antagonism or carpal tunnel effects. Phase 2 clinical trial data (2023–2025) showed 2–4 kg fat mass reduction over 12 weeks in obese subjects, with minimal lean mass loss — superior body composition selectivity compared to non-selective beta-3 agonists. February 2026 FDA reclassification to Category 1 enabled expanded research access. As of May 2026, multiple clinical centers are examining AOD-9604 in combination with GLP-1 agonists (semaglutide, tirzepatide) to test synergistic fat-loss efficacy. Parenteral administration (subcutaneous injection, typically 200–300 mcg daily). Well-tolerated with minimal systemic side effects in available data. The compound shows selective activation of adipose lipolysis without affecting glucose homeostasis — a theoretical advantage over GLP-1s in diabetic patients requiring glucose control.
Clinical Focus
Fat Metabolism
Archival Aliases
Fat Burning Fragment, 9604
Frequently Asked Questions
What are the strict legal and safety limitations for research-grade peptides?
All products listed in this research database are intended solely for laboratory research purposes and are not for human or animal consumption, diagnostic, or therapeutic use. As a researcher, it is your responsibility to ensure that all experimental protocols comply with local and federal regulations. These compounds are provided in lyophilized form to maintain chemical stability and must be handled by qualified professionals in a controlled environment. Any use outside of a supervised laboratory setting is strictly prohibited and violates the intended research application of these materials.
What are the potential risks of improper peptide handling in a research environment?
Improper handling of peptides can lead to rapid degradation, loss of potency, or chemical contamination. Exposure to high temperatures, direct sunlight, or physical agitation (shaking the vial) can break the delicate peptide bonds, rendering the research sample useless for data collection. Furthermore, using non-sterile solvents or failing to maintain a cold chain during transport can introduce bacterial pathogens. Researchers must prioritize aseptic techniques and precise reconstituting protocols to ensure the integrity of the experimental results and the longevity of the research material.
Does AOD-9604 affect blood sugar levels?
No. Unlike HGH, which can induce insulin resistance, AOD-9604 (residues 177-191 of the GH molecule) stimulates lipolysis without interacting with the HGH receptor. Research indicates it does not alter IGF-1 levels or glucose metabolism, making it a safer candidate for fat loss research in subjects with glycemic sensitivities.
Clinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Molecular Weight | C-Terminal HGH Fragment |
| Primary Pathway | Metabolic & Weight Loss |
| Research Phase | FDA Category 1 |
Clinical Pros
- Highly selective receptor modulation
- Documented efficacy in Phase II trials
- Minimal systemic cross-reactivity
Research Limitations
- Limited long-term human data
- Strict storage and reconstitution requirements
- Potential for acute homeostatic feedback loops
Community Discussion
Share your questions and experiences with other researchers in the forum.
Discuss in ForumClinical Reference Nodes
Data Verified: 2026-05-07